Industryweek 4623 Big Pharma
Industryweek 4623 Big Pharma
Industryweek 4623 Big Pharma
Industryweek 4623 Big Pharma
Industryweek 4623 Big Pharma

Big Pharma Loses in 'Pay-To-Delay' Supreme Court Case

June 17, 2013
The justices said litigants could challenge the individual deals in court on a case-by-case basis. "Courts reviewing such agreements should proceed by applying the "rule of reason," rather than under a 'quick look' approach," the Supreme Court decision said.

WASHINGTON—U.S. pharmaceutical companies can be sued for making deals that keep the cost of drugs high by delaying the creation of less expensive generic medications, the U.S. Supreme Court ruled today.

So-called "pay-for-delay" arrangements, which allow drug manufacturers to keep cheaper generics off the market for a time, are "unusual, and there is reason for concern that such settlements tend to have significant adverse effects on competition," read the decision written by Associate Justice Stephen Breyer.

The decision, while finding the payments anti-competitive, did not go so far as to find the practice illegal.

"This court declines to hold that reverse payment settlement agreements are presumptively unlawful," the court said.

But the justices said litigants could challenge the individual deals in court on a case-by-case basis.

"Courts reviewing such agreements should proceed by applying the "rule of reason," rather than under a 'quick look' approach," the Supreme Court decision said.

Equivalent of Hush Money

The U.S. government had argued before the court in March that pay-to-delay was tantamount to big drug manufacturers buying off competitors.

The Federal Trade Commission and the Justice Department argued that such arrangements are tantamount to a decision not to compete, and end up costing consumers billions of dollars each year.

The court heard the case of drugmaker Solvay, a subsidiary of Abbott Laboratories (IW 1000/118), which paid $42 million a year to three generic drug manufacturers—Par, Watson and Paddock—in exchange for their postponing until 2015 generic versions of Solvay's hormonal treatment Androgel.

The generic formulations of Androgel were to be priced at between 15% and 25% of the price of the brand name drug produced by Solvay, which stood to lose some $125 billion.

Drug makers for their part argue that the arrangement allows them sufficient time to recoup expensive research and marketing costs that they incurred with their products.

Copyright Agence France-Presse, 2013

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!